Insights into JAK2-V617F mutation in CML

Lancet Oncology

Volumn 8, Issue 10, 2007, Pages 863-864

  Büsche, Guntram ^a   Hussein, Kais ^a   Bock, Oliver ^a   Kreipe, Hans ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; PHENYLALANINE; VALINE;

ALLELE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL;

FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION;

EID: 34748900022     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70294-2     Document Type: Letter

References (10)

1. Krämer A., Reiter A., Kruth J., et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 8 (2007) 658-660
2. James C., Ugo V., Le Couedic J., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
3. Buesche G., Hehlmann R., Hecker H., et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia-prospective long-term results from a randomized-controlled trial. Leukemia 17 (2003) 2444-2453
4. Buesche G., Freund M., Hehlmann R., et al. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. Leukemia 18 (2004) 1460-1467
5. Hussein K., Bock O., Seegers A., et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 109 (2007) 4106-4107
6. Inami M., Inokuchi K., Okabe M., et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21 (2007) 1103-1104
7. Bornhauser M., Mohr B., Oelschlaegel U., et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21 (2007) 1824-1826
8. Fialkow P., Martin P., Najfeld V., Penfold G., Jacobson R., and Hansen J. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 58 (1981) 158-163
9. Kralovics R., Teo S., Li S., et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108 (2006) 1377-1380
10. Haq A. Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol 35 (1990) 110-113